Target intelligence / Profile preview

MHC class I and class II antigen presentation machinery (APM)

Target
APM
Molecular classification
Other
01

Overview

The MHC class I and class II antigen presentation machinery (APM) is a highly coordinated, multi-step cellular system responsible for processing intracellular and extracellular proteins into peptide fragments and displaying them on major histocompatibility complex (MHC) molecules at the cell surface. This machinery is fundamental to adaptive immunity, enabling CD8+ cytotoxic T cells and CD4+ helper T cells to survey the proteome for signs of infection, foreign antigens, or malignant transformation. Key components of this machinery include the immunoproteasome (for peptide generation), the Transporter associated with Antigen Processing (TAP) complex (for peptide translocation into the endoplasmic reticulum), the peptide-loading complex (including tapasin, calreticulin, and ERp57), and the MHC class I and II molecules themselves. In oncology, many tumors downregulate or mutate components of the APM (such as B2M or TAP1) to evade immune detection, leading to resistance against immune checkpoint inhibitors. Consequently, therapeutic strategies targeting the APM aim to restore or enhance its function using epigenetic modulators (like HDAC or DNMT inhibitors), EZH2 inhibitors, or cytokines (such as interferons) to increase tumor immunogenicity and overcome immune escape. Conversely, proteasome inhibitors like bortezomib directly disrupt this machinery to induce apoptosis in malignant cells.

Other names
Antigen processing and presentation machineryAntigen presentation machineryMHC processing pathwayMHC class I and II antigen presentation pathwayAntigen processing and presentation pathway
02

Mechanism of action

Upregulation of MHC class I and II expression via epigenetic modulation, inhibition of proteasomal degradation of antigen precursors, and induction of antigen presentation machinery components via interferon signaling

03

Biological functions

Immune responseAntigen processingAntigen presentationT cell activationImmune surveillanceProtein degradation
04

Disease associations

CancerInfectionAutoimmune diseaseInflammation
05

Safety considerations

Risk of autoimmune reactions due to increased self-antigen presentationSystemic toxicity associated with epigenetic modulatorsPotential for cytokine release syndrome (CRS)Acquired resistance through genomic loss of MHC components (e.g., B2M deletion)
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

MHC class I expressionMHC class II expressionBeta-2 microglobulin (B2M) expressionTAP1 expressionTAP2 expressionTumor mutational burden (TMB)CD8+ T-cell infiltration

Beyond the preview

Go deeper on MHC class I and class II antigen presentation machinery (APM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MHC class I and class II antigen presentation machinery (APM).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call